Structure via PubChem · Public domain (PubChem)
daclatasvir
Sign in to saveAlso known as BMS-790052, BMS 790052, BMS790052, Dimethyl N,N'-(biphenyl-4,4'-diylbis{1H-imidazole-5,2-diyl-((2S)-pyrrolidine-2,1- diyl)((1S)-1-(1-methylethyl)-2-oxoethane-2,1-diyl)})dicarbamate, EBP 883, N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester, Daklinza
Daclatasvir, sold under the brand name Daklinza, is an antiviral medication used in combination with other medications to treat hepatitis C (HCV). The other medications used in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus type and whether the person has cirrhosis. It is taken by mouth.
Key facts
- Drug.image
- Daclatasvir.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 275
- Drug.tradename
- Daklinza
- Drug.MedlinePlus
- a615044
- Drug.DailyMedID
- Daclatasvir
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AP07
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.bioavailability
- 67%
- Drug.protein_bound
- 99%
- Drug.metabolism
- CYP3A
via Wikipedia infobox
Chemical data
- Formula
- C40H50N8O6
- Molecular weight
- 738.9 g/mol
- IUPAC name
- methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
- SMILES
- CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
- InChIKey
- FKRSSPOQAMALKA-CUPIEXAXSA-N
- XLogP
- 5.1
- Polar surface area
- 175 Ų
- H-bond donors
- 4
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Research
1,557 papers- Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.Clinical pharmacokinetics · 2018
- Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation.Expert opinion on pharmacotherapy · 2023
- Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.The Journal of antimicrobial chemotherapy · 2021
- Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.The Annals of pharmacotherapy · 2016
- Daclatasvir for the treatment of chronic hepatitis C.Expert opinion on pharmacotherapy · 2015
via PubMed
~14 min read
Encyclopedic overview
13 sectionsContents
- Medical use
- Adverse effects
- Interactions
- Pharmacology
- The role of NS5A in HCV replication
- Mechanism of action
- Pharmacokinetics
- History
- Synthesis
- Society and culture
- Economics
- Research
- References
{{Infobox drug | image = Daclatasvir.svg | image_class = skin-invert-image | width = 275 | alt = | caption =
| pronounce = | tradename = Daklinza | Drugs.com = | MedlinePlus = a615044 | DailyMedID = Daclatasvir | pregnancy_AU = B3 | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATC_prefix = J05 | ATC_suffix = AP07
Excerpted from Wikipedia’s “daclatasvir” article, available under the CC BY-SA 4.0 licence.